期刊文献+

曲古抑菌素A抑制小鼠CD4^+T细胞活化的机制 被引量:3

Trichostatin A inhibits the activation of CD_4^+ T cells by suppressing CD_(28) expression in mice
下载PDF
导出
摘要 目的研究组蛋白去乙酰化酶抑制剂曲古抑菌素A(TSA)对小鼠脾脏CD4+T细胞相关分子的基因转录和表达以及对活化信号转导途径的影响,探讨TSA影响CD4+T细胞活化的作用机制。方法采用2、20、200 nmol/L倍比浓度TSA作用于C57BL小鼠脾脏中分离出的CD4+T细胞24 h,观察对CD3,CD28以及IL-2基因转录和表达的影响;观察TSA对采用抗CD3,CD28单抗激活CD4+T细胞表达蛋白酶ZAP70和PI3K的影响。结果 TSA能抑制CD4+T细胞CD28基因转录和分子表达,且与作用浓度相关;能抑制抗体激活的小鼠CD4+T细胞表达PI3K蛋白,而对CD3分子活化信号下游的ZAP70蛋白的表达无明显影响;TSA还能抑制CD4+T细胞IL-2的基因转录和显著减少激活的CD4+T细胞表达IL-2(P<0.01)。结论 TSA通过抑制CD28基因转录和分子表达,影响激活CD4+T细胞活化过程中共刺激信号向细胞内的传导,减少IL-2的分泌,从而降低CD4+T细胞的免疫活性。 Objective To investigate the mechanism of trichostatin A(TSA),a histone deacetylase(HDAC) inhibitor,in inhibiting the activation of CD4+ T cells in mice.Methods The CD4+ T cells isolated from the spleen of C57BL mice were treated with different concentrations of TSA(2,20,and 200 nmol/L) for 24 h,and CD3,CD28 and interleukin-2(IL-2) mRNA levels were measured with reverse transcription-polymerase chain reaction.The protein expressions of CD3,CD28 and IL-2 were measured by fluorescence-activated cell sorting and ELISA analysis.ZAP70 and PI3K protein expression in CD4+ T cells activated by CD3 and CD28 monoclonal antibody were analyzed by Western blotting.Results TSA dose-dependently inhibited the transcription and protein expression of CD28 in CD4+ T cells and reduced the expression of PI3K protein in activated CD4+ T cells,without showing significant effect on the expression of ZAP70.TSA treatment of the cells also resulted in significantly decreased mRNA and protein expressions of IL-2(P0.01).Conclusion TSA can regulate the immunological activity of CD4+ T cells by inducing mRNA and protein expressions of CD28,which inhibits the activation of the co-stimulatory signal transduction in CD4+ T cells and decreases the secretion of IL-2.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2011年第3期423-428,共6页 Journal of Southern Medical University
基金 国家自然科学基金(30940072) 广东省自然科学基金(7300389) 广东省医学科研基(B2008114)~~
关键词 曲古抑菌素A CD4+T细胞 去乙酰化酶抑制剂 信号转导 trichostatin A CD4+ T cells histone deacetylase inhibitor signal transduction
  • 相关文献

参考文献3

二级参考文献12

  • 1Foumel M, Trachy-Bourget MC, Yah PT, et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors [J]. Cancer Res, 2002, 62: 4325-30.
  • 2Dangond F, Gullans SR. Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate [ J ]. Biochem Biophys Res Commun, 1998, 247(3):833-7.
  • 3Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses [J]. BMC Cancer, 2003, 3:30.
  • 4Koyama Y, Adachi M, Sekiya M, et al. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis [ J ]. Blood, 2000, 96:1490-5.
  • 5Lu J, Sun H, Wang X, et al. Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDACI and p300 [ J ]. Cytokine, 2005, 31:46-51.
  • 6Leng C, Gries M, Ziegler J,et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1 [J]. Exp Hematol, 2006, 34:776-87.
  • 7Tian L, Qu X, Wang ME, et al. Selective inhibition of IL-2 mRNA blocks aUografl rejection by limiting T cell clonal expansion [J]. Transplant Proc, 2001, 33:330.
  • 8Bohmig GA, Krieger PM, Saemann MD, et al. Stable prodrugs of n-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allografl survival in a fully allogeneic rat strain combination[ J]. Transplant Immunol, 1999, 7:221-7.
  • 9Chiba T, Yokosuka O, Fukai K, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells [J]. Oncology, 2004,66(6) : 481-491.
  • 10Kozlowska A, Jagodzinski PP. Effect of Trichostatin A on CD4 surface density in peripheral blood T cells [ J]. Folia Histochem Cytobiol, 2006,44(4) :259-262.

共引文献42

同被引文献37

  • 1林洁,来茂德.DNA甲基化、组蛋白去乙酰化与基因表达抑制[J].临床与实验病理学杂志,2006,22(3):353-357. 被引量:16
  • 2唐丽琴,魏伟.组蛋白去乙酰化酶抑制剂与炎症免疫性疾病[J].中国药理学通报,2007,23(1):1-4. 被引量:5
  • 3Adjei AA.Pemetrexed(ALIMTA),a novel multitargeted antineo-plastic agen[t J].Clin Cancer Res,2004,10(12 Pt 2):4276-80s.
  • 4Ikeda H,Chamoto K,Tsuji T,et al.The critical role of type-1 innateand acquired immunity in tumor immunotherapy[J].CancerScience,2004,95:697-703.
  • 5Calvert H.An overview of folate metabolism:features relevant tothe action and toxicities of antifolate anticancer agents[J].SeminOncol,1999,26:3-10.
  • 6Adjei AA.Clinical studies of pemetrexed and gemcitabinecombination[s J].Ann Oncol,2006,17(Suppl 5):v29-32.
  • 7Vogelzang NJ,Rusthoven JJ,Symanowski J,et al.Phase III studyof pemetrexed in combination with cisplatin versus cisplatin alonein patients with malignant pleural mesothelioma[J].J Clin Oncol,2003,21:2636-44.
  • 8Nakagawa K,Yamazaki K,Kunitoh H,et al.Efficacy and safety ofpemetrexed in combination with cisplatin for malignant pleuralmesothelioma:a phase I/II study in Japanese patients[J].Jpn J ClinOncol,2008,38(5):339-46.
  • 9Gronberg BH,Bremnes RM,Flotten O,et al.Phase III study by theNorwegian lung cancer study group:pemetrexed plus carboplatincompared with gemcitabine plus carboplatin as first-linechemotherapy in advanced non-small-cell lung cancer[J].J ClinOncol,2009,27:3217-24.
  • 10Hermiston ML,Tan AL,Gupta VA,et al.The juxtamembranewedge negatively regulates CD45 function in B cells[J].Immunity,2005,23:635-47.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部